Jeffrey W. Albers - Nov 22, 2023 Form 3/A - Amendment Insider Report for Spyre Therapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
SYRE
Transactions as of
Nov 22, 2023
Transactions value $
$0
Form type
3/A - Amendment
Date filed
12/8/2023, 04:03 PM
Date Of Original Report
Nov 27, 2023
Previous filing
Nov 3, 2023
Next filing
Nov 28, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SYRE Series A Preferred Stock Nov 22, 2023 Common Stock 34.4K By Sessions LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations.

Remarks:

This amendment is being filed to report the shares of Series A Preferred Stock that were beneficially owned by the Reporting Person as of November 22, 2023, which were inadvertently omitted in the original Form 3.